BioMed Central Blog

A new home for experimental stroke research

Today has seen the launch of Experimental & Translational Stroke Medicine, a journal dedicated to the gathering and dissemination of new knowledge in the field of experimental stroke research, with the aim of improving the quality of stroke research and facilitating the successful translation of novel treatment strategies into clinical practice.

Amongst the first articles to be published in the journal are detailed reviews on potential new drug candidates currently nearing the end of development such as the hematopoietic factors G-CSF (Minnerup et al), and EPO (Byts and Siren). A detailed review is given by Dr Linker and Dr Lee on recent MS models which are more clinically relevant than the established experimental autoimmune encephalitis. In addition, Dr Gee and colleagues provide clear-cut evidence regarding the possible detrimental effects of the mucosal administration of antigen in terms of autoimmunity.

With their primary aim being to improve the quality of research in this field and reduce translational failure from bench to beside, Editor-in-Chief Wolf-Rüdiger Schäbitz and Deputy Editor Christoph Kleinschnitz explain in their launch editorial how they believe that the open access format BMC offers "is ideally suited to rapidly and broadly disseminating novel findings and promoting fruitful discussion amongst active stroke researchers" and how they would like to “encourage the stroke community to make full use of this very welcome resource”.

For further information about the journal, please visit the journal’s website or view the instructions for authors if you would like to submit a manuscript.

Posted by Sally Robertson at 13:45    Comments (0)